Metabolomics Workbench : NIH Data Repository

Clustering data with heatmap algorithm for (Study ST002354)

This analysis uses the 'heatmap.2' function of gplots package in the R statistics environment

The rows are scaled to have mean=0 and standard deviation=1

Factors:

F1	Genotype:F344 Pirc \| Treatment:200 ppm Naproxen \| Metabolite:Eicosanoid \| Tissue:Plasma
F2	Genotype:F344 Pirc \| Treatment:200 ppm Naproxen \| Metabolite:Eicosanoid \| Tissue:Tumor-adjacent normal colon
F3	Genotype:F344 Pirc \| Treatment:200 ppm Naproxen \| Metabolite:Fatty Acid \| Tissue:Plasma
F4	Genotype:F344 Pirc \| Treatment:200 ppm Naproxen \| Metabolite:Fatty Acid \| Tissue:Tumor-adjacent normal colon
F5	Genotype:F344 Pirc \| Treatment:AIN-93G (control) \| Metabolite:Eicosanoid \| Tissue:Plasma
F6	Genotype:F344 Pirc \| Treatment:AIN-93G (control) \| Metabolite:Eicosanoid \| Tissue:Tumor-adjacent normal colon
F7	Genotype:F344 Pirc \| Treatment:AIN-93G (control) \| Metabolite:Fatty Acid \| Tissue:Plasma
F8	Genotype:F344 Pirc \| Treatment:AIN-93G (control) \| Metabolite:Fatty Acid \| Tissue:Tumor-adjacent normal colon
F9	Genotype:F344 Pirc \| Treatment:EPA-FFA (2%) + 200 ppm Naproxen \| Metabolite:Eicosanoid \| Tissue:Plasma
F10	Genotype:F344 Pirc \| Treatment:EPA-FFA (2%) + 200 ppm Naproxen \| Metabolite:Eicosanoid \| Tissue:Tumor-adjacent normal colon
F11	Genotype:F344 Pirc \| Treatment:EPA-FFA (2%) + 200 ppm Naproxen \| Metabolite:Fatty Acid \| Tissue:Plasma
F12	Genotype:F344 Pirc \| Treatment:EPA-FFA (2%) + 200 ppm Naproxen \| Metabolite:Fatty Acid \| Tissue:Tumor-adjacent normal colon
F13	Genotype:F344 Pirc \| Treatment:EPA-FFA (2% EPA) \| Metabolite:Eicosanoid \| Tissue:Plasma
F14	Genotype:F344 Pirc \| Treatment:EPA-FFA (2% EPA) \| Metabolite:Eicosanoid \| Tissue:Tumor-adjacent normal colon
F15	Genotype:F344 Pirc \| Treatment:EPA-FFA (2% EPA) \| Metabolite:Fatty Acid \| Tissue:Plasma
F16	Genotype:F344 Pirc \| Treatment:EPA-FFA (2% EPA) \| Metabolite:Fatty Acid \| Tissue:Tumor-adjacent normal colon
F17	Genotype:F344 Pirc \| Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen \| Metabolite:Eicosanoid \| Tissue:Plasma
F18	Genotype:F344 Pirc \| Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen \| Metabolite:Eicosanoid \| Tissue:Tumor-adjacent normal colon
F19	Genotype:F344 Pirc \| Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen \| Metabolite:Fatty Acid \| Tissue:Plasma
F20	Genotype:F344 Pirc \| Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen \| Metabolite:Fatty Acid \| Tissue:Tumor-adjacent normal colon
F21	Genotype:F344 Pirc \| Treatment:HD TP-252 (3% EPA) \| Metabolite:Eicosanoid \| Tissue:Plasma
F22	Genotype:F344 Pirc \| Treatment:HD TP-252 (3% EPA) \| Metabolite:Eicosanoid \| Tissue:Tumor-adjacent normal colon
F23	Genotype:F344 Pirc \| Treatment:HD TP-252 (3% EPA) \| Metabolite:Fatty Acid \| Tissue:Plasma
F24	Genotype:F344 Pirc \| Treatment:HD TP-252 (3% EPA) \| Metabolite:Fatty Acid \| Tissue:Tumor-adjacent normal colon
F25	Genotype:F344 Pirc \| Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen \| Metabolite:Eicosanoid \| Tissue:Plasma
F26	Genotype:F344 Pirc \| Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen \| Metabolite:Eicosanoid \| Tissue:Tumor-adjacent normal colon
F27	Genotype:F344 Pirc \| Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen \| Metabolite:Fatty Acid \| Tissue:Plasma
F28	Genotype:F344 Pirc \| Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen \| Metabolite:Fatty Acid \| Tissue:Tumor-adjacent normal colon
F29	Genotype:F344 Pirc \| Treatment:LD TP-252 (1.5% EPA) \| Metabolite:Eicosanoid \| Tissue:Plasma
F30	Genotype:F344 Pirc \| Treatment:LD TP-252 (1.5% EPA) \| Metabolite:Eicosanoid \| Tissue:Tumor-adjacent normal colon
F31	Genotype:F344 Pirc \| Treatment:LD TP-252 (1.5% EPA) \| Metabolite:Fatty Acid \| Tissue:Plasma
F32	Genotype:F344 Pirc \| Treatment:LD TP-252 (1.5% EPA) \| Metabolite:Fatty Acid \| Tissue:Tumor-adjacent normal colon

Data matrix